Oxybutynin (low-dose extended release)
Treatment for Menopause
Typical Dosage: 2.5-5mg extended-release orally once daily
Effectiveness
60%
Safety Score
55%
Clinical Trials
8
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
2.5-5mg extended-release orally once daily
Time to Effect
2-4 weeks
Treatment Duration
Long-term, as needed
Evidence Quality
MODERATENumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
500(Treat 500 patients to see 1 additional serious adverse event)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$330
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$660
Cost per Remission
$1,650
Oxybutynin (low-dose extended release) Outcomes
for Menopause
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+50%
Remission Rate
+20%
Common Side Effects
Dry mouth
+25%
Constipation
+15%
Dizziness
+7%
Blurred vision
+7%
Somnolence
+7%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov